USFDA Pulls Up Cipla For Manufacturing Lapses At Pithampur Plant


“This warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals..Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated,” it noted.



Leave a Comment